From Earlier: BioCryst Announces Positive Results from Its Ongoing BCX4208 Phase 2B Study in Patients with Gout

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) yesterday announced long-term results from the extension phase of its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid therapeutic goal of <6 mg/dL on allopurinol alone.

The results of this 24-week, blinded safety extension confirm that BCX4208 was generally safe and well-tolerated, and sustained sUA control over time. Patients generated healthy immune responses to a vaccine challenge at 16 or 20 weeks of BCX4208 treatment. Following the successful outcome of this 24-week analysis, BioCryst is preparing for end of Phase 2 regulatory discussions to take place in the coming months.